Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SOHONOS® safely and effectively. See full prescribing information for SOHONOS. SOHONOS (palovarotene) capsules, for oral use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).
- generic_name
- palovarotene
- product_names
- palovarotene
- ndc
- 15054-0010, 15054-0010-1, 15054-0015, 15054-0015-1, 15054-0025, 15054-0025-1, 15054-0050, 15054-0050-1, 15054-0100, 15054-0100-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en